Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Adjuvant Therapy and Neoadjuvant Therapy for Melanoma
share announcement

Adjuvant Therapy and Neoadjuvant Therapy for Melanoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 June 2025 | Viewed by 1910

Special Issue Editor

Dr. Michele Del Vecchio

E-Mail Website
Guest Editor
Melanoma Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
Interests: adjuvant therapy; melanoma; clinical trial

Special Issue Information

Dear Colleagues,

Adjuvant therapy and neoadjuvant therapy are two types of treatment used for melanoma, a type of skin cancer. Adjuvant therapy is used after primary treatment, such as surgery, to prevent the cancer from returning. It may involve chemotherapy, radiation therapy, or targeted therapy. Neoadjuvant therapy, on the other hand, is used before primary treatment in order to shrink the tumor and make it easier to remove. This may involve the same types of treatment as adjuvant therapy. Both adjuvant and neoadjuvant therapies have shown promising results in improving survival rates for patients with melanoma. This special issue will highlight clinical research on therapeutic strategies in melanoma.

Dr. Michele Del Vecchio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adjuvant therapy
  • neoadjuvant therapy
  • melanoma
  • skin cancer
  • treatment
  • survival

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1401 KiB  
Article
Role of Postoperative Radiotherapy in the Management of Localized Head and Neck Mucosal Melanoma
by Bong Kyung Bae, Jin Ho Sohn, Dongbin Ahn, Gil Joon Lee, Ji Hye Kwak, Junhee Park and Jeong Eun Lee
Cancers 2025, 17(8), 1284; https://doi.org/10.3390/cancers17081284 - 10 Apr 2025
Viewed by 215
Abstract
Background/Objectives: To evaluate the role of postoperative radiotherapy (PORT) in the management of localized head and neck mucosal melanoma (HNMM). Methods: We retrospectively reviewed 33 patients who underwent surgery for localized HNMM between 2006 and 2023. PORT was delivered to affected anatomical structures, [...] Read more.
Background/Objectives: To evaluate the role of postoperative radiotherapy (PORT) in the management of localized head and neck mucosal melanoma (HNMM). Methods: We retrospectively reviewed 33 patients who underwent surgery for localized HNMM between 2006 and 2023. PORT was delivered to affected anatomical structures, and elective nodal irradiation was not performed. Treatment outcomes, including local recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS), were analyzed. Results: After surgery, 14 patients (41.4%) received PORT. During follow-up, 87.9% of patients experienced recurrence, with local and distant failures being the most common. PORT significantly improved LRFS (p = 0.047) but did not impact PFS or OS. PORT (HR 0.14, p = 0.005) and resection margin status (HR 8.71, p < 0.001) were significantly associated with LRFS in multivariable analysis. Conclusions: PORT for localized HNMM improved local control. Regional recurrence was rare (one patient, 3.4%) even though ENI was not performed. PORT without ENI could improve clinical outcomes for localized HNMM. Full article
(This article belongs to the Special Issue Adjuvant Therapy and Neoadjuvant Therapy for Melanoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 886 KiB  
Review
Female Oncofertility and Immune Checkpoint Blockade in Melanoma: Where Are We Today?
by Cha Len Lee, Erika Martinez, Diego Malon Gimenez, Thiago Pimentel Muniz, Marcus Otho Butler and Samuel David Saibil
Cancers 2025, 17(2), 238; https://doi.org/10.3390/cancers17020238 - 13 Jan 2025
Viewed by 978
Abstract
The incidence of melanoma among young adults has risen, yet mortality has declined annually since the introduction of immune checkpoint inhibitors (ICI). The utilization of peri-operative ICI has significantly altered the treatment landscape in melanoma, with PD-1 inhibitors showing promising efficacy in improving [...] Read more.
The incidence of melanoma among young adults has risen, yet mortality has declined annually since the introduction of immune checkpoint inhibitors (ICI). The utilization of peri-operative ICI has significantly altered the treatment landscape in melanoma, with PD-1 inhibitors showing promising efficacy in improving relapse-free survival rates in high-risk stage II-III disease. With the increasing use of ICI, secondary concerns have emerged regarding the impact of cancer drugs on fertility and reproductive health among women of childbearing potential, especially in early-stage cancer settings. The exclusion of pregnant women from trials contributes to limited human data and clinical uncertainties, such as maternal and fetal toxicities related to ICI exposure during pregnancy, as well as the value of fertility preservation before ICI therapy. Uncertainty persists regarding pregnancy post-adjuvant immunotherapy, given the potential detrimental effects of hormonal and immunological changes during pregnancy on melanoma relapse. There is additional uncertainty about whether pregnancy-associated melanoma (PAM) represents a distinct disease entity that warrants tailored management compared to non-pregnant cases. Our review aims to give an overview of oncofertility practices among female melanoma patients after immunotherapy. We also focus on the literature gap in the published evidence and synthesize summaries regarding ICI toxicities on reproductive health and fetal development, pregnancy planning, and recurrence risks after melanoma treatment. Full article
(This article belongs to the Special Issue Adjuvant Therapy and Neoadjuvant Therapy for Melanoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop